Table 7.
Ongoing lenalidomide-maintenance trials.
| Name | Phase | Age | Histology | Drugs | Status |
|---|---|---|---|---|---|
| NCT01035463 | I/II | >19 ys | Relapsed or refractory NHL | R-BEAM + ASCT + mL | Ongoing and recruiting |
| NCT01035463 | I/II | >18 ys | Relapsed or refractory NHL | R-BEAM + ASCT + mL | Ongoing and recruiting |
| NCT01254578 | I | >18 ys | High-risk hematologic cancers after Allo-SCT | mL | Ongoing and recruiting |
| NCT01045928 | I/II | >18 ys | NHL | R + mL | Ongoing not recruiting |
| NCT01021423 | III | >18 ys | Untreated MCL | FCR or R-CHOP + mL | Ongoing not recruiting |
| IIL MCL0208 | III | 18–60 ys | Untreated MCL | R-BEAM + ASCT + mL | Ongoing and recruiting |
R-BEAM: rituximab, BCNU, etoposide, ara-C, melphalan; ASCT: autologous stem cell transplantation; mL: lenalidomide maintenance; R: rituximab; FCR: fludarabine, cyclophosphamide; rituximab; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.